Mealey's (March 10, 2020, 8:33 AM EDT) -- WASHINGTON, D.C. — One week after Justice Samuel A. Alito Jr. granted an application by a group of pharmaceutical firms to stay a portion of a trial court’s discovery order in a multidistrict price-fixing litigation, the full U.S. Supreme Court on March 6 denied the application and vacated the justice’s order, allowing discovery to continue despite the drug companies’ assertion that the discovery order improperly requires them to produce materials before they have the opportunity to object on the basis of relevance or responsiveness in violation of Federal Rule of Civil Procedure 26(b)(1) (Actavis Holdco Inc., et al. v. Connecticut, et al., No. 19-1010, U.S. Sup., 2020 U.S. LEXIS 1515)....